The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 577-586

  He, Suqin ^a   Smith, Donald L ^a   Sequeira, Manuel ^a   Sang, Jim ^a   Bates, Richard C ^a   Proia, David A ^a  

^a Synta Pharmaceuticals Corp   (United States)

Author keywords

Colorectal cancer; Combination therapy; Ganetespib; HSP90 inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; FLUOROURACIL; GANETESPIB; HEAT SHOCK PROTEIN 90; RADIOSENSITIZING AGENT; TRIAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA REPAIR; DRUG EFFECTS; DRUG SCREENING; FEMALE; HCT116 CELL LINE; HUMAN; IONIZING RADIATION; MOUSE; NUDE MOUSE; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DNA DAMAGE; DNA REPAIR; FEMALE; FLUOROURACIL; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904543801     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0095-4     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63:11-30
2. Cummings LC, Cooper GS (2011) Colorectal cancer screening: update for 2011. Semin Oncol 38:483-489
3. Aparo S, Goel S (2012) Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 83:47-58
4. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11:515-528
5. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772 (Pubitemid 41400776)
6. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549
7. Xu W, Neckers L (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13:1625-1629 (Pubitemid 46952925)
8. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15:9-14
9. Taldone T, Gozman A, Maharaj R, Chiosis G (2008) Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8:370-374
10. Li Y, Zhang T, Schwartz SJ, Sun D (2009) New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 12:17-27
11. Ying W, Du Z, Sun L, Foley KP, Proia DA et al (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11:475-484
12. Zhou D, Liu Y, Ye J, Ying W, Ogawa LS et al (2013) A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. Toxicol Appl Pharmacol 273:401-409
13. Proia DA, Sang J, He S, Smith DL, Sequeira M et al (2012) Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Investig New Drugs 30:2201-2209
14. Acquaviva J, Smith DL, Sang J, Friedland JC, He S et al (2012) Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 11:2633-2643
15. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ et al (2012) Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 18:4973-4985
16. Friedland JC, Smith DL, Sang J, Acquaviva J, He S et al (2013) Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Investig New Drugs 32:14-24
17. Proia DA, Zhang C, Sequeira M, Jimenez JP, He S et al (2014) Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clin Cancer Res 20:413-424
18. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J et al (2013) Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 42:35-43
19. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic Vet al (2013) A multicenter Phase II study of ganetespib monotherpay in patients with genotypically-defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068-3077
20. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M et al (2013) Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 3:430-443
21. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F et al (2013) A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 13:152
22. Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M et al (2014) Overcoming acquired BRAF inhibitor resistance inmelanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther 13:353-363
23. Tse AN, Carvajal R, Schwartz GK (2007) Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13:1955-1960 (Pubitemid 46649860)
24. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18:64-76
25. Kline CL, El-Deiry WS (2013) Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 6:988-1038
26. El Zouhairi M, Charabaty A, Pishvaian MJ (2011) Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 4:15-21
27. Nagaraju GP, Park W, Wen J, Mahaseth H, Landry J et al (2013) Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis 16:903-917
28. da Rocha DS, Friedlos F, Light Y, Springer C, Workman P et al (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65:10686-10691 (Pubitemid 41713335)
29. Pakneshan S, Salajegheh A, Smith RA, Lam AK (2013) Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45:346-356
30. Thiel A, Ristimaki A (2013) Toward a molecular classification of colorectal cancer: the role of BRAF. Front Oncol 3:281
31. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A et al (2013) BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on Patients' outcome. PLoS One 8:e84604
32. Cercek A, Shia J, Gollub M, Raasch PJ, Hollywood E et al (2012) Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer. J Clin Oncol 30:467
33. Machida H, Matsumoto Y, Shirai M, Kubota N (2003) Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 79:973-980 (Pubitemid 38147058)
34. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A et al (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:8984-8995 (Pubitemid 38064080)
35. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ (2003) Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 9:3749-3755 (Pubitemid 37169244)
36. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM et al (2008) HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 7:1985-1992
37. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F et al (2010) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 126:1216-1225
38. Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Yet al (2013) Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther 14:347-356
39. Segawa T, Fujii Y, Tanaka A, Bando S, Okayasu R et al (2014) Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med 33:559-564
40. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429 (Pubitemid 38340288)
41. Catenacci DV, Kozloff M, Kindler HL, Polite B (2011) Personalized colon cancer care in 2010. Semin Oncol 38:284-308
42. Hirsch BR, Zafar SY (2011) Capecitabine in the management of colorectal cancer. Cancer Manag Res 3:79-89
43. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61:5193-5201 (Pubitemid 32681553)
44. Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S et al (2007) Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther 6:2868-2878 (Pubitemid 350206765)
45. Lee KH, Lee JH, Han SW, Im SA, Kim TY et al (2011) Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 102:1388-1395
46. Grothey A, Lenz HJ (2012) Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol 30:1735-1737